Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-Associated Macular Degeneration
Latest Information Update: 08 May 2025
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
Most Recent Events
- 24 Mar 2022 New trial record